Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367016 · ClinicalTrials.gov registry record · Phase 4
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
A Phase 4 study of Asthma and Atopic Dermatitis, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00367016 is a Phase 4 study of Asthma and Atopic Dermatitis that has completed, run by University of California, Davis. The registered enrollment target is 6 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00367016, a Phase 4 study of Asthma and Atopic Dermatitis, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omalizumab
Study Locations (1)
California
- UC Davis Department of Dermatology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-02 |
| Est. Completion | 2012-10-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367016
The ClinicalTrials.gov registry entry for NCT00367016 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00367016 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00367016 about?
NCT00367016 is a clinical study titled "Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)". The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
What is the current status of trial NCT00367016?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2004-02. Estimated completion is 2012-10-17.
What conditions does trial NCT00367016 study?
This clinical trial studies the following conditions: Asthma, Atopic Dermatitis, Allergic Rhinitis.
What interventions are being tested in trial NCT00367016?
The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00367016?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00367016 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.